iron succinate

Absorption

The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.

Toxicity

Acute iron overdosage can be divided into four stages. In the first stage, which occurs up to six hours after ingestion, the principal symptoms are vomiting and diarrhea. Other symptoms include hypotension, tachycardia and CNS depression ranging from lethargy to coma. The second phase may occur at 6-24 hours after ingestion and is characterized by a temporary remission. In the third phase, gastrointestinal symptoms recur accompanied by shock, metabolic acidosis, coma, hepatic necrosis and jaundice, hypoglycemia, renal failure and pulmonary edema. The fourth phase may occur several weeks after ingestion and is characterized by gastrointestinal obstruction and liver damage. In a young child, 75 milligrams per kilogram is considered extremely dangerous. A dose of 30 milligrams per kilogram can lead to symptoms of toxicity. Estimates of a lethal dosage range from 180 milligrams per kilogram and upwards. A peak serum iron concentration of five micrograms or more per ml is associated with moderate to severe poisoning in many.

The Uses of iron succinate

Iron succinate is an oral iron supplement for the treatment of iron deficiency (ID). Iron succinate increases ferritin and transferrin saturation in non-anaemic heart failure and iron deficient patients and can significantly increase iron uptake in patients with heart failure (HF), nearly doubling ferritin levels and increasing TSAT. Patients with HFrEF or HFpEF appear to have a similar response^[1].

Indications

Used in preventing and treating iron-deficiency anemia.

Pharmacokinetics

The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.

Metabolism

Not Available

storage

2-8°C

References

[1] K. BOMAN  M. O. Iron Succinate Increased Ferritin and Transferrin Saturation in Non-Anaemic Patients with Heart Failure and Iron Deficiency—A Pilot Study[J]. World Journal of Cardiovascular Diseases, 2021, 11 1: 11-19. DOI:10.4236/WJCD.2021.111002.